In a ground-breaking $100m deal with Canadian Cronos Group, a Boston company called Ginkgo Bioworks has been charged with perfecting the process of producing synthetic cannabinoids from organisms, such as yeast, that have been genetically altered.
According to The Guardian, the modified organisms would act as the engines that convert the raw components into the desired cannabis compounds, such as THC and CBD. Yeast plays that role in the brewing of beer and the Boston company is confident they can learn from those processes of beer brewing for these cannabis-focused purposes.
While it certainly presents challenges, the science involved is established, said Ginkgo’s head of business development, Jess Leber. “It’s something we can wrap our heads around pretty readily.”